

1 **Evaluation of a standard protocol for drying off and drying off therapy in dairy**  
2 **cows based on the comparison of two different commercial antimicrobials**

3 Turini L<sup>1</sup>, Fratini F<sup>1,2</sup>, Conte G<sup>3</sup>, Turchi B<sup>1</sup>, Cerri D<sup>1,2</sup>, Bertelloni F<sup>1</sup>, Bonelli F<sup>1</sup>

4 <sup>1</sup>Dipartimento di Scienze Veterinarie, University of Pisa, Italy. <sup>2</sup>Interdepartmental  
5 Research Center “Nutraceuticals and Food for Health”, Via del Borghetto 80, University  
6 of Pisa (Italy). <sup>3</sup>Dipartimento di Scienze Agrarie, Alimentari e Agro-ambientali,  
7 University of Pisa, Italy.

8

9 Running title:

10 Drying off therapy in a dairy farm

11 Turini et al.

12

13

14

15

16 Corresponding author:

17 Dr. Luca Turini

18 Dipartimento di Scienze Veterinarie,

19 Viale delle Piagge 2, 56122, Pisa, Italy

20 Phone number: +390502210115, Fax: +390502210654

21 Email: [luca.turini@phd.unipi.it](mailto:luca.turini@phd.unipi.it)

22 ORCID: 0000-0002-4164-8263

## 23 **Abstract**

24 This study aims to evaluate two commercial antibiotics for dry-off. Ninety-five Friesian  
25 cows and 380 quarters were included. Cows were classified as Control and Subclinical  
26 Mastitis based on somatic cell count. The California Mastitis Test and the teat end score  
27 have been performed. Quarters were randomly treated with Cloxacillin and Ampicillin  
28 (TA) and Cephalexin (TB). The effect of the therapy (TA vs TB) was estimated by X<sup>2</sup>  
29 analysis based on the Wald test. The preservative and therapeutic action of TA vs TB  
30 were evaluated by the Kruskal-Wallis test. TB showed a statistically significant  
31 therapeutic effect in the control group, that might be related to the pharmacological  
32 activity of the two antibiotics. Also, the subclinical mastitis group most commonly  
33 presented more quarters affected compared to the control group, leading to a worse  
34 improvement despite proper therapy. In conclusion, an abruptly dried off, the California  
35 mastitis test, teat end score and somatic cell count evaluation, as long as microbial herd  
36 data might represent key concepts for an efficient drying off standard protocol in a dairy  
37 farm. In line with the herd bacterial population, both TA and TB might be employed for  
38 drying off therapy.

39 **Key words:** Veterinary, dairy cow, mastitis, dry period, drying-off therapy.

40

41

## 42 **Introduction**

43 The dry period is defined as the nonlactating period prior to parturition in dairy cows.  
44 Usually, this period begins at the end of the lactation curve, whom shape, and length is  
45 strongly influenced by several environmental and genetic factors (Macciotta et al.  
46 2011). The length of the dry period is about 60 days in Europe and United States of

47 America (Capuco et al. 1997; Annen et al. 2004). The dry period has a critical role for  
48 udder health, due to an increased risk of intra-mammary infections (IMI) during this  
49 time (Bradley and Green 2000; Whist and Østeras 2007). Despite a good dry period  
50 management, some animals appear more prone to new IMI than others and may show  
51 clinical mastitis in the next lactation (Hogan and Smith 2003). The most frequently  
52 isolated microorganisms at dry-off are *Streptococcus* spp., coagulase-negative  
53 staphylococci (CNS), *Staphylococcus aureus* and *Corynebacterium* spp. (Pantoja et al.  
54 2009). Dry cow therapy (DCT) is an intra-mammary treatment with an antibiotic,  
55 administered at the beginning of the dry period. Since many years, the treatment of IMI  
56 at drying off has been a basis for mastitis control and management (Bradley and Green  
57 2000). Dry cow therapy eliminates existing IMI and preventing new IMIs (Bradley and  
58 Green 2000; Dingwell et al. 2004; Whist and Østeras 2007). The elimination of  
59 infection and the prevention of new IMI in the dry period is easier than during lactation.  
60 The drug is not milked out, so the antibiotic can remain longer in the udder. Moreover,  
61 the absence of regular milking reduces the exposition to pathogens by teat penetration  
62 (Berry et al. 2004; Kashif et al. 2016).

63 The most common drugs used as dry-off therapy are intra-mammary tubes containing  
64 antibiotics such as penicillin, cloxacillin, cephalosporin and spiramycin (Kashif et al.  
65 2016). Despite the large amount of literature about dry-off therapy strategies, usually  
66 the decision concerning which antibiotic therapy would be better in a specific herd is  
67 still made by drug popularity and farmer's preference and not based on scientific  
68 evidences.

69 The aims of the present study were to evaluate the effects of two different commercial  
70 antibiotics at dry-off in the same herd on the mammary microbiological populations, in  
71 order to set a standard protocol for the dry off therapy in line with isolated bacteria.

## 72 **Materials and methods**

### 73 *Animals*

74 The present study was carried out in an intensive dairy farm located in the North of  
75 Italy. A total of 108 Italian Holstein Friesian cows in the same management conditions  
76 were considered for the trial. An owner's written consent for participating on the study  
77 have been recorded. All the experimental procedure were in compliance with the  
78 2010/63/UE directive about the protection of animals in the scientific experiments.  
79 Cows were between 210 and 220 days of gestation and were considered healthy based  
80 on the complete physical examination. Animals included in the trial were not subjected  
81 to antibiotic and/or nonsteroidal anti-inflammatory drugs (NSAIDs) treatments for 30  
82 days period before the admission time and did not showed udder or milk abnormalities  
83 at dry-off. All the included animals were observed from drying-off until 15 days of  
84 lactation. The drying off standard protocol proposed in this study has been carried out as  
85 follow. All eligible cows were dried off abruptly. During the last milking session, the  
86 teat end score (TESa) was recorded for each quarter as reported in literature (Hamann  
87 and Mein 1996; Neijenhuis et al. 2000), along with the udder evaluation. The California  
88 Mastitis Test (CMTa) was used as the screening test for clinical or subclinical mastitis  
89 detection (Barnum and Newbould 1961). A sample has been considered positive for  
90  $CMT \geq 1$  (Blowey and Edmondson 2010). Before the antibiotic administration, a sterile  
91 milk sample for bacteriologic analysis was collected from positive CMT quarter in a 15  
92 mL tubes (Falcon®, BD, Italy) and was stored at  $4^{\circ}\text{C} \pm 2^{\circ}\text{C}$  until the time of analysis.

93 All the samples were processed within 3 hours. After these evaluations, the animals  
94 were treated with Cloxacillin and Ampicillin (Cloxalene Max, Fatro, Italy), or  
95 Benzathine Cephalexin (Rilexine, 500 HL, Virbac, Italy) as drying-off therapy, despite  
96 the CMT results. Dry-off cows were then transferred to a separate box, located in a  
97 different barn. The dry-cow's box was composed by a pen for the daily exercise, in  
98 between the feeding area, where all animals were fed at the same time. Moreover, in this  
99 area there was a resting zone composed by an appropriate number of cubicles bedded  
100 with daily-changed straw. At dry-off, cows were fed a low energy density diet,  
101 administered as total mixed ration (TMR) two times per day (Table 1). At the inclusion  
102 time, animals were divided in two groups (Treatment A and Treatment B) based on the  
103 drugs supply at the farms. Treatment A (TA) quarters received 600 mg of Cloxacillin  
104 and 300 mg of Ampicillin (Cloxalene Max, Fatro, Italy), while treatment B (TB)  
105 quarters received 375 mg of Benzathine Cephalexin (Rilexine, 500 HL, Virbac, Italy).  
106 The whole 4 quarters of a single cow were treated with the same antibiotic. For a better  
107 classification of the cows, the average somatic cells count (SCCa) of the 4 quarters has  
108 been evaluated at the inclusion time by the MilkoScan (FOSS, Italy). Thus, animals  
109 were retrospectively classified as "C cows" when the SCC was  $< 150'000$  cells/mL for  
110 primiparous and  $< 250'000$  cells/mL for multiparous cows and as "SCM cows" when  
111 the SCC was  $> 150'000$  cells/mL for primiparous and  $> 250'000$  cells/mL for  
112 multiparous (de Haas et al. 2008; Windig et al. 2010). The "C cows" has been  
113 considered as control animals. A second evaluation took place 15 days after parturition  
114 for each quarter included. The same parameters collected at the inclusion time were  
115 considered: 1) teat end score for each quarter (TESb); 2) CMT performed for each

116 quarter 15 days after parturition (CMTb); 3) the average SCC (SCCb) of each single  
117 quarter.

### 118 *Bacteriology analysis*

119 To isolate the mastitis agents and to screening the microbials population of the studied  
120 herd, 0.01 mL of each CMTa positive milk sample was streaked on blood agar plates  
121 containing 10% sheep blood. Each plate was incubated aerobically at 37 °C for 24-48 h.  
122 After observation of colony morphology and hemolytic patterns on blood agar, isolates  
123 were submitted to Gram staining, catalase and oxidase testing and additional  
124 biochemical and metabolic evaluations as needed.

125 Gram-negative organisms were successively identified by sowing on appropriate  
126 selective and differential media; furthermore, enzyme activities, acid production from  
127 different carbohydrates, assimilation of various substrates were determined using  
128 commercial systems- API ZYM, API 20E and API 20NE (BioMerieux ®) according to  
129 the manufacturer's instructions.

130 *Staphylococcus* spp., grown on Baird Parker medium with the typical halo associated  
131 with lecithinase positivity and characterized by typical zones of complete and  
132 incomplete hemolysis and nonhemolytic *Staphylococcus* spp. that had a positive tube  
133 test for free coagulase were classified as *Staphylococcus aureus*; all other staphylococci  
134 were classified as CNS. Moreover, all isolates belonging to *Staphylococcus* genus were  
135 also identified using API Staph (BioMerieux ®). The other Gram-positive cocci, grown  
136 on blood agar plates and negative for catalase test, were phenotypically identified by  
137 means of API 20 Strep (BioMerieux ®).

### 138 *Statistical analysis*

139 Data concerning SCCa and SCCb, CMTa and CMTb, type of treatment (TA vs TB) and  
140 TESa and TESb of C and SCM groups were expressed as prevalence.

141 Data obtained in this work were analyzed by R software (R Development Core Team).

142 Firstly, the effect of the therapy (use of the antibiotics TA or TB) on the number of  
143 positive or negative teats to CMTa were estimated by  $\chi^2$  analysis based on the Wald  
144 test. The analysis was repeated both for cows classified as “C” or “SCM”.

145 Subsequently, we estimated the different effect of the two antibiotics by the non-  
146 parametric Kruskal-Wallis test. This analysis was repeated in two different situations:  
147 firstly, we evaluated the protective action of the two antibiotics considering the  
148 percentage of negative CMT teats that remain unchanged after the treatment; while the  
149 therapeutic effect was estimated considering the percentage of positive CMT teats that  
150 became negative after treatment.

## 151 **Results**

152 A total of 380 quarter in 95 cows were included, from 46 primiparous cows (48%) and  
153 49 multiparous cows (52%). Thirteen animals from the 108 enrolled were excluded  
154 from the study for the presence of only three functional udder quarters or because of  
155 treatments during the 30 days before the inclusion time. Cows were in first to fifth  
156 lactation, with an average of 4.5 (3-7) years old, average body weight of 660 kg (520-  
157 710) and average body condition score (BCS) of 3.25 (2.5-3.75).

158 One hundred and thirty-six/380 quarters (referred to 34 cows) received TA while  
159 244/380 quarters (referred to 61 cows) were treated with TB. Based on SCCa  
160 evaluation, a total of 29 cows (18 primiparous and 11 multiparous) were included in the  
161 C group, while 66 cows (28 primiparous and 38 multiparous) were included in the SCM  
162 group. A total of 32 quarters belong to C group were treated with TA, while 84 quarters

163 were treated with TB. A total of 104 quarters belong to SCM group were treated with  
164 TA, while 160 quarters were treated with TB. Data concerning SCCa, CMTa and TESa  
165 of C and SCM groups were reported in Table 2.

166 A total of 68 out of 380 milk samples were CMTa positive, thus they were sampled for  
167 bacteriologic analysis. Fiftythree out of 68 milk samples (78%) were culture negative, 9  
168 (13%) were positive for environmental pathogens (CNS and Serratia), while the  
169 remaining 6 samples (9%) were positive for contagious pathogens. The pH was out of  
170 the normal range (6.5-6.7) in 41 out of 68 (60%) milk samples (Ruegg e Erskine, 2015).  
171 The average pH value was  $6.8 \pm 0.2$ .

172 Results concerning CMTb and TESb of C and SCM cows, grouped based on SCCa are  
173 reported in Table 3, while results concerning CMTb and TESb of C and SCM cows,  
174 grouped based on SCCb are reported in Table 4.

175 Results concerning changing between CMTa vs CMTb in TA vs TB cows, classified  
176 based on SCCa are reported in Table 5.

177 Table 6 showed the result of contingency analysis related to the number of quarters  
178 treated with TA and TB. Statistical differences between expected and observed number  
179 of quarters were revealed for SCM cows ( $p < 0,001$ ) with higher number of positive  
180 quarters observed for TA.

181 Results concerning the effect of the different antibiotic on teat in a preventive  
182 (expressed as % of teats that continued to show CMT negative after treatment) and  
183 therapy (expressed as % of teats that showed CMT negative after treatment) are  
184 reported in Table 7. Different effect between the two treatments was only observed only  
185 for the C cows ( $p = 0,022$ ) during therapeutic action, while no difference was revealed

186 for SCM cows ( $p = 0,990$ ). On the contrary, the preventive effect was similar between  
187 TA and TB.

## 188 **Discussion**

189 Dry period is crucial for two different reasons: 1) high rates of IMIs healing during this  
190 period and 2) the develop rates of new IMIs during this period are higher than during  
191 the lactating period (Dingwell et al. 2003; Halasa et al. 2009). For these reasons,  
192 intramammary antibiotics are used to treat any existing IMI at dry-off and to prevent  
193 new IMI during the dry period. However, the choice of the best antibiotics therapy  
194 would be set according to the kind of mammary pathogens. Prudent use of antibiotics is  
195 recommended to prevent the development of antimicrobial resistance. The isolation of  
196 different pathogens and their sensitivity or resistance to some antibiotics is the key to  
197 choose the most suitable antibiotics to avoid the antimicrobial resistance (Scherpenzeel  
198 et al. 2014). The whole population of this study presented no udder or milk  
199 abnormalities at the dry-off but only CMT alterations, with a prevalence for subclinical  
200 mastitis of 18%, which is slightly lower value compared with data reported in literature  
201 (Busato et al. 2000; Giannechini et al. 2002). However, our study only evaluated cows  
202 at drying-off, while data presented in literature usually came from the screening of the  
203 whole herd. This might explain the differences in results. Reported prevalence of  
204 infection at dry-off, due to any pathogen, ranges from 28 % to 50 % at cow level  
205 (Rindsig et al. 1978; Browning et al. 1994). Our results are slightly lower compared  
206 with other authors. However, the incidence of infections at dry-off in a herd could be  
207 influenced by many factors and this might explain the differences found in prevalence  
208 (Torres et al. 2008).

209 Otherwise, the high prevalence of subclinical mastitis obtained in this study, confirmed  
210 that subclinical mastitis still represents an important problem in the dairy cow industry  
211 (Pisoni 2007). Thus, screening for subclinical mastitis at the time of dry-off is  
212 mandatory for keeping a high standard of udder and milk health and hygiene.  
213 The screening method choose in the present study was the CMT because it still  
214 represents the commonest used one in the field (Ruegg e Erskine 2015). Also, literature  
215 recommended the use of CMT for identification of IMI when herd prevalence of IMI is  
216 lower than 15% (Torres et al. 2008). Authors knew the average prevalence of IMI from  
217 the history of the herd. However, samples CMT positive were tested for BE and the  
218 prevalence of positive BE was 22%. Despite CMT is largely used in dairy practice, our  
219 results confirmed the too high sensibility of the test (Bradley et al. 2012; Zecconi and  
220 Zanirato 2013; Sgorbini et al. 2014). The CMT may be influenced by several factors,  
221 i.e. the time of sampling (morning vs evening) or the season (summer vs fall) (Bradley  
222 et al. 2012; Zecconi and Zanirato 2013), the storage and processing of the sample  
223 (Viguiet et al. 2009; Bradley et al. 2012), udder inflammation other than infectious  
224 problems (i.e. trauma, alimentary management, milking procedures) (Zecconi and  
225 Zanirato 2013). Thus, for a more proper use of antibiotic therapy at dry-off, the BE  
226 might be considered the gold standard test for drive the decision (Ruegg and Erskine  
227 2015). *Staphylococcus* spp. was the most common bacterium isolated in our population,  
228 as confirmed by literature (Torres et al. 2008; Zecconi and Zanirato 2013; Ruegg and  
229 Erskine 2015). Compared with TA, TB showed a statistically significant therapeutic  
230 effect in “C cows” while no difference where observed for “SCM cows”. Cloxacillin  
231 (TA) represents one of the most widely used antibiotics for the drying off in dairy cows  
232 (Halasa et al. 2009; Bhutto et al. 2011). However, Cephalexin (TB) has been

233 successfully used in the treatment of subclinical mastitis of lactating cows (Tiwari et al.  
234 2000). The difference in therapeutic effect found in the present study might be related to  
235 the pharmacological activity of the two antibiotics. Also, “SMC cows” most commonly  
236 had affected more quarters than “C cows”, leading to a worse improvement despite a  
237 proper therapy. Further studies with an increasing number of animals included might  
238 complete the present findings.

### 239 **Conclusions**

240 In conclusion, an abruptly dried off, the CMT, TEC and SCC evaluation, as well as  
241 microbiological examination might represent key concepts for an efficient drying off  
242 standard protocol in a dairy farm. The SCC evaluation is essential to find subclinical  
243 mastitis and to decide to treat the single quarter of the udder. The pathogens isolations  
244 before the drying off is the key to choose the ideal antimicrobial to treat it. In line with  
245 the herd bacterial population, both TA and TB might be employed for drying off therapy.

### 246 **Acknowledgement and/or disclaimers, if any**

247 This research did not receive any specific grant from funding agencies in the public,  
248 commercial, or not-for-profit sectors.

### 249 **References**

- 250 1. Annen, E. L., R. J. Collier, M. A. McGuire, J. L. Vicini, J. M. Ballam, M. J.  
251 Lormore (2004): Effect of modified dry period lengths and bovine somatotropin  
252 on yield and composition of milk from dairy cows. *J. Dairy Sci.* 87, 3746–3761.  
253 [https://doi.org/10.3168/jds.S0022-0302\(04\)73513-4](https://doi.org/10.3168/jds.S0022-0302(04)73513-4)
- 254 2. Barnum, D. A., F. H. S. Newbould (1961): The use of the California Mastitis Test  
255 for the detection of bovine mastitis. *Can. Vet. J.* 2, 83–90.

- 256 3. Berry, E. A., H. Hogeveen, J. E. Hillerton (2004): Decision tree analysis to  
257 evaluate dry cow strategies under UK conditions. *J. Dairy Res.* 71, 409–418.  
258 <https://doi.org/10.1017/S0022029904000433>
- 259 4. Bhutto, A. L., R. D. Murray, Z. Woldehiwet (2011): The effect of dry cow therapy  
260 and internal teat-sealant on intra-mammary infections during subsequent  
261 lactation. *Res. Vet. Sci.* 90, 316–320.  
262 <https://doi.org/10.1016/j.rvsc.2010.06.006>
- 263 5. Blowey, R., P. Edmondson (2010): Somatic cell count. In: *Mastitis control in*  
264 *Dairy Herds* (Blowey, R., P. Edmondson P, Eds), 2<sup>nd</sup> Edition, CABI, UK, pp. 153-  
265 170.
- 266 6. Bradley, A. J., M. J. Green (2000): A study of the incidence and significance of  
267 intramammary enterobacterial infections acquired during the dry period. *J. Dairy*  
268 *Sci.* 83, 1957-1965.  
269 [https://doi.org/10.3168/jds.S0022-0302\(00\)75072-7](https://doi.org/10.3168/jds.S0022-0302(00)75072-7)
- 270 7. Bradley, A., H. Barkema, A. Biggs, M. Green, T. Lam (2012): Control of mastitis  
271 and enhancement of milk quality. In: *Dairy Herd Health* (Green, D., Eds), CABI,  
272 UK, pp. 117-168.
- 273 8. Browning, J. W., G. A. Mein, P. Brightling, T. J. Nicholls, M. Barton (1994):  
274 Strategies for mastitis control: dry cow therapy and culling. *Aust. Vet. J.* 71, 179–  
275 18.  
276 <https://doi.org/10.1111/j.1751-0813.1994.tb03383.x>
- 277 9. Busato, A., P. Trachsel, M. Schallibaum, J. M. Blum (2000): Udder health and  
278 risk factors for subclinical mastitis in organic dairy farms in Switzerland. *Prev.*  
279 *Vet. Med.* 44, 205–220.

- 280 [https://doi.org/10.1016/S0167-5877\(00\)00104-5](https://doi.org/10.1016/S0167-5877(00)00104-5)
- 281 10. Capuco, A. V., R. M. Akers, J. J. Smith (1997): Mammary growth in Holstein  
282 cows during the dry period: quantification of nucleic acids and histology. *J. Dairy*  
283 *Sci.* 80, 477–487.
- 284 [https://doi.org/10.3168/jds.S0022-0302\(97\)75960-5](https://doi.org/10.3168/jds.S0022-0302(97)75960-5)
- 285 11. de Haas, Y., W. J. Ouweltjes ten Napel, J. J. Windig, G. de Jong (2008):  
286 Alternative somatic cell count traits as mastitis indicators for genetic selection. *J.*  
287 *Dairy Sci.* 91, 2501–2511.
- 288 <https://doi.org/10.3168/jds.2007-0459>
- 289 12. Dingwell, R.T., D. F. Kelton, K. E. Leslie (2003): Management of the dry cow in  
290 control of peripartum disease and mastitis. *Vet. Clin. North Am. Food. Anim.*  
291 *Pract.* 19, 235–265.
- 292 [10.1016/S0749-0720\(02\)00072-5](https://doi.org/10.1016/S0749-0720(02)00072-5)
- 293 13. Dingwell, R.T., K. E. Leslie, Y. H. Schukken, J. M. Sargeant, L. L. Timms, T. F.  
294 Duffield, G. P. Keefe, D. F. Kelton, K. D. Lissemore, J. Conklin (2004):  
295 Association of cow and quarter-level factors at drying-off with new  
296 intramammary infections during the dry period. *Prev. Vet. Med.* 63, 75-89.
- 297 <https://doi.org/10.1016/j.prevetmed.2004.01.012>
- 298 14. Giannechini, R., C. Concha, R. River, I. Delucci, J. Moreno Lopez (2002):  
299 Occurrence of clinical and subclinical mastitis in dairy herds in the west littoral  
300 region in Uruguay. *Acta Vet. Scand.* 43, 221–230.
- 301 <https://doi.org/10.1186/1751-0147-43-221>

- 302 15. Halasa, T., O. Osteras, H. Hogeveen, T. Van Werven, T. Nielsen (2009) Meta-  
303 analysis of dry cow management for dairy cattle. Part1. Protection against new  
304 intramammary infections. *J. Dairy Sci.* 92, 3134-3149.  
305 <https://doi.org/10.3168/jds.2008-1740>
- 306 16. Hamann, J., G. A. Mein (1996): Teat thickness changes may provide biological  
307 test for effective pulsation. *J. Dairy Sci.* 63, 179–189.  
308 <https://doi.org/10.1017/S002202990003168X>
- 309 17. Hogan, J. S., K. L. Smith (2003): Coliform mastitis. *Vet. Res.* 34:507–519.  
310 <https://doi.org/10.1051/vetres:2003022>
- 311 18. Macciotta, N. P. P., C. Dimauro, S. P. G. Rassu, G. Steri, G. Pulina (2011): The  
312 mathematical description of lactation curves in dairy cattle. *Ital. J. Anim. Sci.*  
313 10:51.  
314 <https://doi.org/10.4081/ijas.2011.e51>
- 315 19. Neijenhuis, F., H. W. Barkema, H. Hogeveen, J. P. Noordhuizen (2000):  
316 Classification and longitudinal examination of callused teat ends in dairy cows. *J.*  
317 *Dairy Sci.* 83, 2795–2804.  
318 [https://doi.org/10.3168/jds.S0022-0302\(00\)75177-0](https://doi.org/10.3168/jds.S0022-0302(00)75177-0)
- 319 20. Pantoja, J. C. F., C. Hulland, P. L. Ruegg (2009): Dynamics of somatic cell counts  
320 and intramammary infections across the dry period. *Prev. Vet. Med.* 90, 43-54.  
321 <https://doi.org/10.1016/j.prevetmed.2009.03.012>
- 322 21. Pisoni G (2007) Mastitis in a dairy herd (in Italian). (Point Veterinaire Italie, La  
323 fenice grafica, Eds), Borghetto Lodigiano (Lo), Italy.
- 324 22. Rindsig, R. B., R. G. Rodewald, A. R. Smith, S. L. Spahr (1978): Complete versus  
325 selective dry cow therapy for mastitis control. *J. Dairy Sci.* 61, 483–1497.

- 326 [https://doi.org/10.3168/jds.S0022-0302\(78\)83753-9](https://doi.org/10.3168/jds.S0022-0302(78)83753-9)
- 327 23. Ruegg, P. L., R. J. Erskine (2015): Mammary Gland Health. In: Large Animal  
328 Internal Medicine (Smith, B. P., Eds), 5th ed., Elsevier. St Louis, pp. 1015-1043.
- 329 24. Scherpenzeel, C. G. M., I. E. M. den Uijl, G. van Schaik, R. G. M. Olde Riekerink,  
330 J. M. Keurentjes, T. J. G. M. Lam (2014) Evaluation of the use of dry cow  
331 antibiotics in low somatic cell count cows. *J. Dairy Sci.* 97:3606-3614.  
332 <https://doi.org/10.3168/jds.2013-7655>
- 333 25. Sgorbini, M., F. Bonelli, F. Fratini, A. Sbrana, M. Brombin, V. Meucci, M.  
334 Corazza, V. Ebani, F. Bertelloni, B. Turchi, D. Gatta, D. Cerri (2014): Mastitis in  
335 dairy cattle: a comparison of some screening tests and bacteriology. *Large Anim.*  
336 *Rev.* 20(1), 9-16.
- 337 26. Torres, A. H., P. J. Rajala-Schultz, F. J. DeGraves, K. H. Hoblet (2008): Using  
338 dairy herd improvement records and clinical mastitis history to identify  
339 subclinical mastitis infections at dry-off. *J. Dairy Res.* 75, 240–247.  
340 <https://doi.org/10.1017/S0022029908003257>
- 341 27. Tiwari, A., R. S. Sisodia, K. S. Misraulia (2000): Treatment of subclinical mastitis  
342 in cows with Cephalexin. *Indian J. Vet. Med.* 20(2), 97-98.
- 343 28. Kashif, M., M. Rizwan, M. Ali, T. Ahmad, A. Z. Durrani (2016): Control of  
344 Mastitis through dry cow therapy: A review. *Veterinaria* 2(2), 13-16.
- 345 29. Whist, A. C., O. Østeras (2007): Associations between somatic cell counts at  
346 calving or prior to dry-off and clinical mastitis in the remaining or subsequent  
347 lactation. *J. Dairy Res.* 74, 66-73.  
348 <https://doi.org/10.1017/S0022029906002172>

- 349 30. Windig, J. J., W. Ouweltjes, J. Ten Napel, G. de Jong, R. F. Veerkamp, Y. de Haas  
350 (2010): Combining somatic cell count traits for optimal selection against mastitis.  
351 J. Dairy Sci. 93, 1690–1701.  
352 <https://doi.org/10.3168/jds.2009-2052>
- 353 31. Viguier, C., S. Arora, N. Gilmartin, K. Welbeck, R. O’Kennedy (2009): Mastitis  
354 detection: current trends and future perspectives. Trends Biotechnol. 27, 486–  
355 493.  
356 <https://doi.org/10.1016/j.tibtech.2009.05.004>
- 357 32. Zecconi, A., G. Zanirato (2013): Mastitis control for a sustainable dairy farm (in  
358 Italian) (diVet e GeSan, Eds), pp. 69.  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372

373

374

375

376 **Table 1.** Dry matter concentrations and chemical composition of the close-up dry (CUD)

377 diets fed to Holstein Friesian cows.

378

CUD Diet	
Ingredients	Percentage
Corn silage	45.46
Alfalfa hay	5.00
Corn grains	18.28
Cottonseed hulls	11.17
Soybean meal	8.38
Cottonseed with lint	5.2
Prolak	2.55
Springer minerals	2.92
Salt	0.5
Sodium bicarbonate	0.54
Chemical composition	Percentage (DM basis)
DM (%)	62.07
CP	14.88
Sol CP <sup>1</sup>	29.25
ADF	26.17
NDF	40.53
EE <sup>2</sup>	3.81
TDN	67.22
NE <sub>L</sub> (Mcal/Kg)	1.52
K <sup>+</sup>	1.14
Na <sup>+</sup>	0.40
Cl <sup>-</sup>	0.82
S <sup>-2</sup>	0.33
Ca <sup>+2</sup>	1.07
P <sup>+</sup>	0.38
Calculated DCAD <sup>3</sup>	+19.4

379 <sup>1</sup>Percentage of the CP380 <sup>2</sup>Ether extract381 <sup>3</sup>Meq/100g DM

382

383 **Table 2. Data concerning the evaluation of SCCa, CMTa and TESa scores**  
 384 **performed in C and SCM groups. Legend: SCCa – somatic cells count at inclusion**  
 385 **time (dry-off); CMTa – california mastitis test at inclusion time (dry-off); TESa -**  
 386 **teat score for each quarter; TA – treatment A (600 mg of Cloxacillin and 300 mg of**  
 387 **Ampicillin); TB – treatment B (375mg of Benzathine Cephalexin); C group – control**  
 388 **group; SCM group – subclinical mastitis group.**

389

SCCa (cell/ml)	CMTa	TESa score 1		TESa score 2		TESa score 3		TESa score 4	
		TA	TB	TA	TB	TA	TB	TA	TB
C group	Positive	1/32	0/84	2/32	4/84	0/32	2/84	0/32	0/84
	Negative	26/32	68/84	3/32	10/84	0/32	0/84	0/32	0/84
SCM group	Positive	11/104	4/160	17/104	14/160	2/104	8/160	0/104	3/160
	Negative	54/104	94/160	19/104	32/160	1/104	3/160	0/104	2/160

390

391 **Table 3. Data concerning the evaluation of CMTb and TESb scores performed in C**  
 392 **and SCM grouped based on SCCa. Legend: SCCa – somatic cells count at inclusion**  
 393 **time (dry-off); CMTb – california mastitis test 15 days after parturition; TA –**  
 394 **treatment A (600 mg of Cloxacillin and 300 mg of Ampicillin); TB – treatment B**  
 395 **(375mg of Benzathine Cephalexin); C group – control group; SCM group –**  
 396 **subclinical mastitis group.**

397

SCCa (cell/ml)	CMTb	TESb score 1		TESb score 2		TESb score 3		TESb score 4	
		TA	TB	TA	TB	TA	TB	TA	TB
C group	Positive	3/32	1/84	1/32	3/84	0/32	0/84	0/32	0/84
	Negative	24/32	67/84	4/32	11/84	0/32	2/84	0/32	0/84
SCM group	Positive	6/104	3/160	5/104	8/160	1/104	3/160	0/104	1/160
	Negative	59/104	95/160	31/104	38/160	2/104	8/160	0/104	4/160

398

399 **Table 4. Data concerning the evaluation of CMTb and TESb scores performed in C**  
 400 **and SCM groups based on SCCb. Legend: SCCb – somatic cells count 15 days**  
 401 **after parturition; CMTb – california mastitis test 15 days after parturition; TA –**  
 402 **treatment A (600 mg of Cloxacillin and 300 mg of Ampicillin); TB – treatment B**  
 403 **(375mg of Benzathine Cephalexin); C group – control group; SCM group –**  
 404 **subclinical mastitis group.**

405

SCCb (cell/ml)	CMTb	TESb score 1		TESb score 2		TESb score 3		TESb score 4	
		TA	TB	TA	TB	TA	TB	TA	TB
C group	Positive	1/136	1/244	4/136	0/244	0/136	0/244	0/136	0/244
	Negative	72/136	120/244	23/136	38/244	2/136	7/244	0/136	2/244
SCM group	Positive	6/136	9/244	5/136	5/244	1/136	3/244	0/136	2/244
	Negative	13/136	36/244	9/136	17/244	0/136	3/244	0/136	1/244

406

407 **Table 5. Results concerning changing in CMTa vs CMTb for C and SCM group and**  
 408 **the information about treatments received (TA vs TB). Legend: SCCa – somatic cells**  
 409 **count at inclusion time (dry-off); CMTa – california mastitis test at inclusion time**  
 410 **(dry-off); CMTb – california mastitis test 15 days after parturition; TA – treatment**  
 411 **A (600 mg of Cloxacillin and 300 mg of Ampicillin); TB – treatment B (375mg of**  
 412 **Benzathine Cephalexin); C group – control group; SCM group – subclinical mastitis**  
 413 **group.**

414

	Treatment at dry-off	CMTa-neg vs CMTb-neg		CMTa-pos vs CMTb-pos	
		CMTa-neg vs CMTb-neg	CMTa-neg vs CMTb-pos	CMTa-pos vs CMTb-neg	CMTa-pos vs CMTb-pos
C group	TA	27	2	1	2
	TB	74	4	6	0
SCM group	TA	69	5	23	7
	TB	121	10	24	5

415

416

417

418

419

420 **Table 6. Table of contingency for the estimation of antibiotic treatment effect. The**  
 421 **data refer to the number of treated teats. A) C cows; B) SCM cows.**

A) P=0.297							
	Observed				Expected		
	TA	TB	Total		TA	TB	Total
Positive	3	6	9	Positive	4	5	9
Negative	29	78	107	Negative	28	79	107
Total	32	84	116	Total	32	84	116

  

B) P< 0.001							
	Observed				Expected		
	TA	TB	Total		TA	TB	Total
Positive	30	29	59	Positive	23	36	59
Negative	74	131	205	Negative	81	124	205
Total	104	160	264	Total	104	160	264

422

423 **Table 7. Effect of the different antibiotic on teat in a preventive (expressed as % of**  
 424 **teats that remain negative after treatment) and therapy (expressed as % of teats that**  
 425 **become negative after treatment).**

	TA	TB	SE	P-value
Preventive effect in "C cows"	92.85 %	94.91 %	6.08	0.760
Preventive effect in "SCM cows"	92.68 %	92.37 %	4.14	0.770
Therapeutic effect in "C cows"	50.00 %	100.00 %	14.56	0.022
Therapeutic effect in "SCM cows"	76.61 %	81.60 %	15.84	0.990

426

427

428